¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute Toxicity Tests"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
¿µ¹® acute cholecystitis ÇÑ±Û ±Þ¼º¾µ°³¿°
¼³¸í   
  º¸Åë ¾µ°³ ÃⱸÀÇ Æó»ö¿¡ ÀÇÇÑ °ÍÀ̸ç, ¿°ÁõÀÇ Á¤µµ´Â °æµµÀÇ ºÎÁ¾À¸·ÎºÎÅÍ ±«Àú¿Í Ãµ°øÀ» ¼ö¹ÝÇϴ °¨¿°Áõ±îÁö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • acute hepatitis
    ±Þ¼º°£¿°
  • acute idiopathic polyneuritis
    ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°, ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿°
  • acute intermittent porphyria
    ±Þ¼º°£ÇæÆ÷¸£ÇǸ°Áõ
  • acute ischemic brachial neuropathy
    ±Þ¼ºÇãÇ÷À§ÆÈ½Å°æº´(Áõ), ±Þ¼ºÇãÇ÷»ó¿Ï½Å°æº´(Áõ)
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute necrotizing hemorrhagic encephalopathy
    ±Þ¼º±«»çÃâÇ÷³úº´(Áõ)
  • acute necrotizing retinitis
    ±Þ¼º±«»ç¸Á¸·¿°
  • acute necrotizing ulcerative gingivitis
    ±Þ¼º±«»ç±Ë¾çÀÕ¸ö¿°, ±Þ¼º±«»ç±Ë¾çÄ¡Àº¿°
  • acute nephritis
    ±Þ¼ºÄáÆÏ¿°, ±Þ¼º½ÅÀå¿°
  • acute obliterating bronchiolitis
    ±Þ¼ºÆó¼â¼¼±â°üÁö¿°
  • acute pancreatitis
    ±Þ¼ºÀÌÀÚ¿°, ±Þ¼ºÃéÀå¿°
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute pneumonia
    ±Þ¼ºÆó·Å
  • acute pancreatitis
    ±Þ¼ºÀÌÀÚ¿°, ±Þ¼ºÃéÀå¿°
  • acute pyelonephritis
    ±Þ¼º±ò¶§±âÄáÆÏ¿°, ±Þ¼º½Å¿ì½ÅÀå¿°
  • acute idiopathic polyneuritis
    ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°, ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿°
  • acute salpingitis
    Àڱðü¿°, ³­°ü¿°
  • severe acute respiratory syndrome
    ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute infectious disease
    ±Þ¼º°¨¿°º´
  • acute intermittent porphyria
    ±Þ¼º°£ÇæÆ÷¸£ÇǸ°Áõ
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
  • acute necrotizing retinitis
    ±Þ¼º±«»ç¸Á¸·¿°
  • acute normal tissue effect
    Á¤»óÁ¶Á÷±Þ¼º¿µÇâ
  • acute obliterating bronchiolitis
    ±Þ¼ºÆó¼â¼¼±â°üÁö¿°
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • acute posterior ganglionitis
    (¢¡herpes zoster) ´ë»óÆ÷Áø, ¶ìÇ츣Æä½º
  • acute purulent sinusitis
    ±Þ¼º°í¸§ÄÚ°ç±¼¿°, ±Þ¼ºÈ­³óºÎºñµ¿¿°
  • acute radiation sickness
    ±Þ¼º¹æ»ç¼±º´
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • acute schizophrenic episode
    ±Þ¼ºÁ¤½ÅºÐ¿­º´»ðÈ­
  • acute situational stress reaction
    ±Þ¼º»óȲ½ºÆ®·¹½º¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute anterior poliomyelitis
    ±Þ¼ºÀü°¢¼ºÈ¸¹é¼ö¿°, Æú¸®¿À
  • acute anterior poliomyelitis =infantile par aly sis
    ±Þ¼º ȸ¹éô¼ö¿°(ÐáàõüéÛÜô±âÐæú).
  • acute anxiety neurosis
    ±Þ¼º ºÒ¾È½Å°æÁõ (¡­ÝÕäÌãêÌèñø).
  • acute aortitis
    ±Þ¼º ´ëµ¿¸Æ¿°(¡­´ëµ¿¸Æ¿°).
  • acute aortitis
    ±Þ¼º ´ëµ¿¸Æ¿°(¡­ÓÞÔÑØææú).
  • acute apical periodontitis
    ±Þ¼º ±Ù÷¼º Ä¡ÁÖ¿°(¡­ÐÆôÓàõöÍñ²æú).
  • acute appendicitis
    ±Þ¼º Ãæ¼ö¿°(¡­Ãæ¼ö¿°).
  • acute appendicitis
    ±Þ¼ºÃæ¼ö¿°.
  • acute arthritis
    ±Þ¼º °üÀý¿°(ÐáàõÎ¼ï½æú).
  • acute ascending myelitis
    ±Þ¼º »óÇà(¼º) ô¼ö¿°(¡­ß¾ú¼àõô±âÐæú).
  • acute ascending paralysis<³ª> p. ascendens acu ta
    ±Þ¼º »óÇà(¼º) ¸¶ºñ(¡­ß¾ú¼àõ Ýö).
  • acute ataxia
    ±Þ¼º ¿îµ¿½ÇÁ¶(¡­ê¡ÔÑã÷ðà).
  • acute auditory hallucinosis
    ±Þ¼º ȯûÁõ
  • acute bacterial arthritis
    ±Þ¼º ¼¼±Õ¼º °üÀý¿°(Ðáàõá¬Ð¶àõÎ¼ï½æú).
  • acute bacterial arthritis
    ±Þ¼º ¼¼±Õ¼º °üÀý¿°(¡­á¬Ð¶àõÎ¼ï½æú).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • digitalis toxicity
    µðÁöÅ»¸®½ºµ¶¼º.
  • free radical formation,oxygen toxicity
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »ê¼Òµ¶¼º(ß«áÈÔ¸àõ)
  • halothane, toxicity
    ÇÒ·Îź µ¶¼º
  • occupational toxicity
    Á÷¾÷¼º Áßµ¶(¼º).
  • organ toxicity
    Àå±âµ¶¼º.
  • oxygen toxicity
    »ê¼Òµ¶¼º(¡­Ô¸àõ).
  • oxygen,toxicity
    »ê¼Òµ¶¼º(ß«áÈÔ¸àõ)
  • selective toxicity
    ¼±ÅÃÀû µ¶¼º
  • selective toxicity
    ¼±ÅÃÀû µ¶¼º(àÔ÷ÉîÜÔ¸àõ)
  • subacute toxicity
    ¾Æ±Þ¼º µ¶¼º(¡­Ô¸àõ).
  • toxicity
    µ¶¼º
  • toxicity
    µ¶¼º.
  • toxicity test
    µ¶¼º½ÃÇè.
  • vinca alkaloid toxicity
    ºóÄ« ¾ËÄ®·ÎÀÌµå µ¶¼º(µ¶·Â)
  • acute mixed-lineage leukmia
    ±Þ¼º È¥ÇÕÁ÷°è¼º ¹éÇ÷º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RALT routine admission laboratory tests
SMA-6 Sequential Multiple Analysis-m-six different serum tests
EUROTOX European Committee on Chronic Toxicity Hazards
I&T intolerance and toxicity
TCLP Toxicity Characteristic Leachate Procedure [EPA battery test]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TEF toxicity equivalence factor
BPT Bronchial provocation tests
CPT Conjunctival provocation tests
IVGTT I.v. glucose tolerance tests
IFT Immunofluorescence tests
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute apical abscess
    ±Þ¼º Ä¡±Ù´Ü ³ó¾ç
    µ¿ÀǾî=acute alveolar abscess.
  • acute appendicitis
    ±Þ¼º Ãæ¼ö¿°
    1. Ãæ¼ö¿° ȯÀÚÀÇ 50-80%¿¡¼­ ºÐ¼®
  • acute ascending paralysis
    ±Þ¼º »óÇà ¸¶ºñ, ±Þ¼º »óÇ༺ ¸¶ºñ
  • acute ataxia
    ±Þ¼º ¿îµ¿½ÇÁ¶
    ±ÙÀ° »óÈ£ÇùÁ¶°¡ °á¿©µÇ°Å³ª ±ÙÀ°±â´ÉÀÌ ºÒ±ÔÄ¢ÇÏ¿© ¿îµ¿±â´ÉÀÌ »ó½ÇµÇ´Â °Í.
  • acute atrophic candidiasis
    ±Þ¼º À§Ã༺ ĵµð´ÙÁõ
    ±Þ¼º À§Ã༺ ĵµð´ÙÁõÀÇ º´¼Ò´Â ĵµð´Ù °¨¿°ÀÇ ¶Ç ´Ù¸¥ ÇüÅ·μ­ ÈçÇÑ °ÍÀº ¾Æ´Ï´Ù. ÀÌ º´¼Ò´Â ¹Ýµå½Ã µ¿ÀÏ ÇüÅÂÀÇ È¯ÀÚ Áï ±Þ¼º À§¸·¼º ĵµð´ÙÁõÀ¸·Î ÁøÇàµÇ±â ½¬¿î ȯÀÚ¿¡¼­ ³ªÅ¸³­´Ù. ¶Ç ±¤¹üÀ§ Ç×»ýÁ¦ ½ºÅ×·ÎÀ̵å Á¦Á¦ ¶Ç´Â ¸é¿ª ¾ïÁ¦Á¦¸¦ Åõ¿© ¹Þ´Â ȯÀÚ¿¡¼­µµ ³ªÅ¸³­´Ù. Á¶Á÷ Ç¥º»À» º¸¸é Ç¥ÃþºÎ¿¡ ¼Ò¼öÀÇ ±Õ»ç¸¦ °¡Áö´Â À§Ã༺ »óÇǰ¡ ³ªÅ¸³ª°í °íÀ¯ Ãþ¿¡¼­´Â ´ë°³ °æ¹ÌÇÑ ±Þ¼º ¿°Áõ¼º ħÀ±ÀÌ ³ªÅ¸³ª¸ç Ç÷°üÀÇ ¼ö°¡ Áõ°¡ÇÑ´Ù. ĵµð´ÙÁõ ½Ã ³ªÅ¸³ª´Â º´¼Ò´Â ´Ï½ºÅ¸Æ¾ ±¸°­ Çöʾ×À̳ª ±¸°­ Á¤Á¦·Îµµ »ç¿ëµÇ´Â ´Ï½ºÅ¸Æ¾ Á¤Á¦¸¦ »ç¿ëÇØµµ Àß Ä¡À¯µÈ´Ù.
  • acute auditory hallucinosis
    ±Þ¼º ȯûÁõ
  • acute bacterial endocarditis
    ±Þ¼º ¼¼±Õ¼º ½É³»¸·¿°
  • acute bacterial meningitis
    ±Þ¼º ¼¼±Õ¼º ³ú¸·¿°
  • acute bacterial sialadenitis
    ±Þ¼º ¼¼±Õ¼º Ÿ¾×¼±¿°
  • acute bleeding
    ±Þ¼º ÃâÇ÷
  • acute brain disorder
    ±Þ¼º ³úÀå¾Ö
  • acute bronchitis
    ±Þ¼º ±â°üÁö¿°
    ´Ü±â°£¿¡ ´Ù¼Ò ÁßÁõ °æ°ú¸¦ ÃëÇÏ´Â ±â°üÁöÀÇ ¿°ÁõÀ¸·Î, ¿øÀÎÀº °¨±â¿¡ °É¸®°Å³ª Àڱؼº ¹°ÁúÀÇ ÈíÀÎÀ̳ª ±Þ¼º °¨¿° µîÀ̸ç, ¹ß¿­, È£Èí°ï¶õ, ±âÁú ¹× ±âħ¿¡ µ¿¹ÝÇÏ´Â ÈäºÎ µÎÅë µîÀ» Ư¡À¸·Î ÇÑ´Ù.
  • acute bulbar polioencephalitis
    ±Þ¼º ¿¬¼öȸ¹é³ú¿°
  • acute candidosis
    ±Þ¼º ĵµð´ÙÁõ
    Ä­µð´Ù¼ÓÀÇ ±ÕÀ¸·Î ÀÎÇÑ ±Þ¼º°¨¿°º´.
  • acute care bed
    ÀÀ±Þ Ä¡·á º´»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
breath tests Any tests done on exhaled air.
(12 Dec 1998)
bronchial provocation tests Tests involving inhalation of allergens (nebulised or in dust form), nebulised pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma.
(12 Dec 1998)
caloric tests Elicitation of a rotatory nystagmus by stimulating the saemicircular canals with water or air which is above or below body temperature. In warm caloric stimulation a rotatory nystagmus is developed toward the side of the stimulated ear; in cold, away from the stimulated side. Absence of nystagmus indicates the labyrinth is not functioning.
(12 Dec 1998)
carcinogenicity tests Tests to experimentally measure the tumour-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumours or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumour developed. Though this test differs from the DNA-repair and bacterial microsome mutagenicity tests, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
(12 Dec 1998)
pancreatic function tests Tests based on the biochemistry and physiology of the exocrine pancreas and involving analysis of blood, duodenal contents, feces, or urine for products of pancreatic secretion.
(12 Dec 1998)
gel diffusion precipitin tests Precipitin test's in which the immune precipitate forms in a gel medium (usually agar) into which one or both reactants have diffused; generally classified in two types, in one dimension, and in two dimensions.
Synonym: gel diffusion reactions.
(05 Mar 2000)
gel diffusion precipitin tests in one dimension Precipitin test's in which antigen solution and antibody incorporated in agar are layered in tubes, permitting effective diffusion in the vertical dimension; the antibody-containing agar may be overlaid directly with antigen solution (single (gel) diffusion in one dimension).
(05 Mar 2000)
gel diffusion precipitin tests in two dimensions Precipitin test's made in a layer of agar that permits radial diffusion, in both of the horizontal dimensions, of one or both reactants. Double (gel) diffusion in two dimensions (Ouchterlony test, technique, or method) incorporates antigen and antibody solutions placed in separate wells in a sheet of plain agar, permitting radial diffusion of both reactants; this method is widely used to determine antigenic relationships; the bands of precipitate that form where the reactants meet in optimal concentration are of three patterns, referred to as reaction of identity, reaction of partial identity (cross-reaction), and reaction of nonidentity.
(05 Mar 2000)
patch tests Skin tests in which the sensitiser is applied to a patch of cotton cloth or gauze held in place for approximately 48-72 hours. It is used for the elicitation of a contact hypersensitivity reaction.
(12 Dec 1998)
respiratory function tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
(12 Dec 1998)
personality tests Standardised objective tests designed to facilitate the evaluation of personality.
(12 Dec 1998)
microbial sensitivity tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
(12 Dec 1998)
micronucleus tests Induction and quantitative measurement of chromosomal damage leading to the formation of micronuclei in cells which have been exposed to genotoxic agents or ionizing radiation.
(12 Dec 1998)
clinical chemistry tests Laboratory tests demonstrating the presence of physiologically significant substances in the blood, urine, tissue, and body fluids with application to the diagnosis or therapy of disease.
(12 Dec 1998)
placental function tests Methods used for the assessment of placental function.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á